News
01-20-2011, 05:50 AM
ZIOPHARM Oncology, Inc., announced today that The Committee for Orphan Medicinal Products (COMP) within the European Medicines Agency (EMA) adopted a positive opinion for darinaparsin (Zinapar™ or ZIO-101) designation as an orphan medicinal product for the treatment of peripheral T-cell lymphoma (PTCL).
More... (http://www.news-medical.net/news/20110120/ZIOPHARMs-darinaparsin-receives-EMA-COMP-orphan-drug-designation-for-treatment-of-peripheral-T-cell-lymphoma.aspx)
More... (http://www.news-medical.net/news/20110120/ZIOPHARMs-darinaparsin-receives-EMA-COMP-orphan-drug-designation-for-treatment-of-peripheral-T-cell-lymphoma.aspx)